Skip to main content
CHUGAI PHARMACEUTICAL CO., LTD. logo

CHUGAI PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4519 ISIN · JP3519400000 LEI · 529900T9LAII161DCN95 T Manufacturing
Open in API
Filings indexed 81 across all filing types
Latest filing 2023-07-28 Interim / Quarterly Rep…
Country JP Japan
Listing T 4519

About CHUGAI PHARMACEUTICAL CO., LTD.

https://www.chugai-pharm.co.jp/english/

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Recent filings

Filing Released Lang Actions
四半期報告書－第113期第2四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Chugai Pharmaceutical Co., Ltd. in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MDA), and operational updates for the period from April 1, 2023, to June 30, 2023. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. H1 2023
2023-07-28 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's quarterly report. Per the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type (in this case, a quarterly report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial statements. Q1 2023
2023-04-28 Japanese
四半期報告書－第113期第1四半期(2023/01/01－2023/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial statements, management analysis (MDA), and operational updates for Chugai Pharmaceutical Co., Ltd. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2023
2023-04-28 Japanese
内部統制報告書－第112期(2022/01/01－2022/12/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. This type of document is a standalone regulatory filing concerning audit and internal control standards, which falls under the 'Audit Report / Information' category in the provided schema.
2023-03-30 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It is a mandatory filing that accompanies the Annual Securities Report (Yukashoken Hokokusho) to confirm the accuracy of the report's contents by the CEO and CFO. Since it is a regulatory filing required by law that does not fit into the specific categories of financial reports, presentations, or announcements, it falls under the 'Regulatory Filings' (RNS) category. FY 2022
2023-03-30 Japanese
有価証券報告書－第112期(2022/01/01－2022/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of the US 10-K. It contains comprehensive financial statements, management discussion, and corporate information for the fiscal year ending December 31, 2022. It is a full annual report, not an announcement or a summary. FY 2022
2023-03-30 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.